Acro Biomedical Co annual operating income
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Acro Biomedical Co's operating income was −$154,024 for fiscal 2025.
View full Acro Biomedical Co company overview| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$154,024 | −$116,066 | — |
| 2024 | 2024-12-31 | −$37,958 | $8.8M | — |
| 2023 | 2023-12-31 | −$8.8M | $7.1M | — |
| 2022 | 2022-12-31 | −$15.9M | −$8.2M | — |
| 2021 | 2021-12-31 | −$7.7M | −$7.6M | — |
| 2020 | 2020-12-31 | −$130,463 | $292,288 | — |
| 2019 · Dec 31 | 2019-12-31 | −$422,751 | — | — |
| 2019 · Sep 30 | 2019-09-30 | −$441,553 | −$957,103 | — |
| 2018 | 2018-09-30 | $515,550 | $517,798 | — |
| 2017 | 2017-09-30 | −$2,248 | −$45,676 | — |
| 2016 | 2016-09-30 | $43,428 | — | — |
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$17,554 | −$3,940 | — |
| Q1 2026 | 2026-03-31 | −$60,271 | −$51,337 | — |
| Q4 2025 | 2025-12-31 | −$16,377 | −$6,909 | — |
| Q3 2025 | 2025-09-30 | −$115,099 | −$105,993 | — |
| Q2 2025 | 2025-06-30 | −$13,614 | −$4,528 | — |
| Q1 2025 | 2025-03-31 | −$8,934 | $1,364 | — |
| Q4 2024 | 2024-12-31 | −$9,468 | $7,933 | — |
| Q3 2024 | 2024-09-30 | −$9,106 | $1.6M | — |
| Q2 2024 | 2024-06-30 | −$9,086 | $3.2M | — |
| Q1 2024 | 2024-03-31 | −$10,298 | $4.0M | — |
| Q4 2023 | 2023-12-31 | −$17,401 | $3.9M | — |
| Q3 2023 | 2023-09-30 | −$1.6M | $2.4M | — |
| Q2 2023 | 2023-06-30 | −$3.2M | $801,732 | — |
| Q1 2023 | 2023-03-31 | −$4.0M | −$74,978 | — |
| Q4 2022 | 2022-12-31 | −$3.9M | −$81,283 | — |
| Q3 2022 | 2022-09-30 | −$4.0M | −$1.0M | — |
| Q2 2022 | 2022-06-30 | −$4.0M | −$3.2M | — |
| Q1 2022 | 2022-03-31 | −$3.9M | −$3.9M | — |
| Q4 2021 | 2021-12-31 | −$3.9M | −$3.8M | — |
| Q3 2021 | 2021-09-30 | −$3.0M | −$2.9M | — |
| Q2 2021 | 2021-06-30 | −$793,320 | −$730,549 | — |
| Q1 2021 | 2021-03-31 | −$56,991 | −$138,548 | — |
| Q4 2020 | 2020-12-31 | −$77,708 | −$2,275 | — |
| Q3 2020 | 2020-09-30 | −$71,541 | −$7,081 | — |
| Q2 2020 | 2020-06-30 | −$62,771 | $5,321 | — |
| Q1 2020 | 2020-03-31 | $81,557 | $296,323 | — |
| Q4 2019 · Dec 31 | 2019-12-31 | −$75,433 | $18,802 | — |
| Q4 2019 | 2019-09-30 | −$64,460 | −$225,546 | — |
| Q3 2019 | 2019-06-30 | −$68,092 | −$244,318 | — |
| Q2 2019 | 2019-03-31 | −$214,766 | −$312,777 | — |
| Q1 2019 | 2018-12-31 | −$94,235 | −$174,462 | — |
| Q4 2018 | 2018-09-30 | $161,086 | $121,591 | +307.86% |
| Q3 2018 | 2018-06-30 | $176,226 | $188,113 | — |
| Q2 2018 | 2018-03-31 | $98,011 | $120,454 | — |
| Q1 2018 | 2017-12-31 | $80,227 | $87,640 | — |
| Q4 2017 | 2017-09-30 | $39,495 | — | — |
| Q3 2017 | 2017-06-30 | −$11,887 | $5,238 | — |
| Q2 2017 | 2017-03-31 | −$22,443 | — | — |
| Q1 2017 | 2016-12-31 | −$7,413 | — | — |
| Q3 2016 | 2016-06-30 | −$17,125 | — | — |
Over the last five fiscal years, Acro Biomedical Co's operating income decreased from −$130,463 to −$154,024, a change of −$23,561. The latest reported quarter, Q2 2026, shows −$17,554.
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acro Biomedical Co source filings ↗